$45 million investment creates 200 new jobs and strengthens Wisconsin’s position as a U.S. Regional Tech Hub
MADISON, Wis. — October 3, 2025 — Governor Tony Evers, together with the Wisconsin Economic Development Corporation (WEDC), joined Catalent leaders today to celebrate the company’s $45 million expansion of its Madison facilities. The project, which includes facility improvements and new equipment, has already created approximately 200 new, highly skilled biohealth jobs, reinforcing Wisconsin’s growing reputation as a national leader in biopharmaceutical innovation.
To support the expansion, WEDC has authorized up to $2 million in performance-based business development tax credits, contingent on job creation and capital investment milestones.
“Catalent is a perfect example of how Wisconsin’s world-class workforce, outstanding educational institutions, and culture of innovation combine to make our state a leader in biohealth and biopharma,” said Gov. Evers. “This expansion is an incredible win for local families, our growing biohealth sector, and the state as a whole.”
Catalent, a global leader in enabling pharmaceutical, biotech, and consumer health partners to develop, launch, and scale treatments, produces billions of doses of life-saving therapies annually. The company’s Madison facility houses GPEx® Lightning cell line technology, state-of-the-art manufacturing labs, and flexible production capabilities ranging from 50 to 4,000 liters.
“Catalent’s continued growth in Madison demonstrates the strength of Wisconsin’s biohealth ecosystem,” said WEDC Secretary and CEO Missy Hughes. “The company’s decision to expand here underscores our ability to provide the skilled workforce and supportive environment needed to power breakthroughs in biotechnology.”
Catalent executives emphasized that Wisconsin’s designation as a U.S. Regional Technology Hub by the U.S. Economic Development Administration in 2023 was a key factor in the decision to expand. That designation, secured under Gov. Evers’ leadership, is expected to generate more than 30,000 direct jobs and 111,000 indirect jobs over the next decade, driving nearly $9 billion in economic development statewide.
“We are proud to expand in Madison, a growing hub for innovation and collaboration,” said David McErlane, Catalent Group President of Biologics. “This community provides us with exceptional talent and a supportive business environment to continue serving our global partners and the patients who rely on us.”
This marks the fourth time Wisconsin has supported Catalent’s growth, including past tax credit awards for expansions in 2011, 2017, and 2019, which together have created more than 600 jobs.
With this latest investment, Wisconsin further cements its place as a biohealth and biopharmaceutical powerhouse, contributing to national competitiveness in one of the fastest-growing and most impactful industries of the 21st century.
More information about the EDA’s Tech Hubs program is available here .
About Catalent
Catalent is a global leader in enabling pharmaceutical, biotech, and consumer health partners to optimize product development, launch, and supply chain. With cutting-edge facilities worldwide, Catalent delivers billions of doses of life-enhancing treatments annually.
About Wisconsin Economic Development Corporation (WEDC)
WEDC is Wisconsin’s lead economic development agency, committed to advancing innovation, entrepreneurship, and growth across the state. Through strategic investments, WEDC strengthens industries, builds regional hubs, and ensures Wisconsin businesses thrive.
